Mannkind (MNKD) Operating Leases (2019 - 2026)
Mannkind (MNKD) posted quarterly Operating Leases of $10.3 million for Q1 2026, down 7.72% year-over-year from $11.1 million in Q1 2025, and down 3.82% quarter-over-quarter from $10.7 million in Q4 2025.
Mannkind (MNKD) Operating Leases (2019 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Operating Leases for 8 consecutive years, with $10.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 7.72% year-over-year to $10.3 million; the TTM figure through Mar 2026 stood at $10.3 million (down 7.72% YoY), while the FY2025 annual figure was $10.7 million, down 8.21% from the prior year.
- Operating Leases eased to $10.3 million in Q1 2026 per MNKD's latest filing, from $10.7 million in the prior quarter.
- Across five years, Operating Leases topped out at $12.2 million in Q3 2024 and bottomed at $826000.0 in Q1 2022.
- Historically, Operating Leases has averaged $7.0 million across 5 years, with a median of $5.7 million in 2022.
- Annual changes were most pronounced in 2022 — Operating Leases soared 951.06% — and 2024, when it fell 29.57%.
- Mannkind's Operating Leases stood at $5.3 million in 2022, then dropped by 26.54% to $3.9 million in 2023, then jumped by 196.69% to $11.6 million in 2024, then slipped by 8.21% to $10.7 million in 2025, then declined by 3.82% to $10.3 million in 2026.
- Business Quant data shows MNKD's Operating Leases at $10.3 million in Q1 2026, $10.7 million in Q4 2025, and $10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.69 Mn |
| Mar 31, 2026 | 10.28 Mn |
| Dec 31, 2025 | 10.69 Mn |
| Sep 30, 2025 | 10.26 Mn |
| Jun 30, 2025 | 10.66 Mn |
| Mar 31, 2025 | 11.14 Mn |
| Dec 31, 2024 | 11.65 Mn |
| Sep 30, 2024 | 12.17 Mn |
| Jun 30, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.65 Mn |
| Dec 31, 2023 | 3.93 Mn |
| Sep 30, 2023 | 4.29 Mn |
| Jun 30, 2023 | 4.65 Mn |
| Mar 31, 2023 | 4.88 Mn |
| Dec 31, 2022 | 5.34 Mn |
| Sep 30, 2022 | 5.67 Mn |
| Jun 30, 2022 | 5.93 Mn |
| Mar 31, 2022 | 826,000.00 |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | 798,000.00 |